Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 53 (1), 10-19

Peripheral Inflammatory Biomarkers in Alzheimer's Disease: A Brief Review


Peripheral Inflammatory Biomarkers in Alzheimer's Disease: A Brief Review

Jong-Chan Park et al. BMB Rep.


Alzheimer's disease (AD) is a chronic neurodegenerative disease characterized by the accumulation of amyloid plaques and neurofibrillary tangles in the brain. The AD pathophysiology entails chronic inflammation involving innate immune cells including microglia, astrocytes, and other peripheral blood cells. Inflammatory mediators such as cytokines and complements are also linked to AD pathogenesis. Despite increasing evidence supporting the association between abnormal inflammation and AD, no well-established inflammatory biomarkers are currently available for AD. Since many reports have shown that abnormal inflammation precedes the outbreak of the disease, non-invasive and readily available peripheral inflammatory biomarkers should be considered as possible biomarkers for early diagnosis of AD. In this minireview, we introduce the peripheral biomarker candidates related to abnormal inflammation in AD and discuss their possible molecular mechanisms. Furthermore, we also summarize the current state of inflammatory biomarker research in clinical practice and molecular diagnostics. We believe this review will provide new insights into biomarker candidates for the early diagnosis of AD with systemic relevance to inflammation during AD pathogenesis. [BMB Reports 2020; 53(1): 10-19].

Conflict of interest statement


The authors have no conflicting interests.


Fig. 1
Fig. 1
Graphical summary of peripheral inflammatory biomarker candidates.

Similar articles

See all similar articles


    1. Heneka MT, Carson MJ, El Khoury J, et al. Neuroinflammation in Alzheimer’s disease. Lancet Neurol. 2015;14:388–405. doi: 10.1016/S1474-4422(15)70016-5. - DOI - PMC - PubMed
    1. Han SH, Park JC, Mook-Jung I. Amyloid beta-interacting partners in Alzheimer’s disease: From accomplices to possible therapeutic targets. Prog Neurobiol. 2016;137:17–38. doi: 10.1016/j.pneurobio.2015.12.004. - DOI - PubMed
    1. Hansen DV, Hanson JE, Sheng M. Microglia in Alzheimer’s disease. J Cell Biol. 2018;217:459–472. doi: 10.1083/jcb.201709069. - DOI - PMC - PubMed
    1. Cagnin A, Brooks DJ, Kennedy AM, et al. In-vivo measurement of activated microglia in dementia. Lancet. 2001;358:461–467. doi: 10.1016/S0140-6736(01)05625-2. - DOI - PubMed
    1. Baik SH, Kang S, Lee W, et al. A Breakdown in Metabolic Reprogramming Causes Microglia Dysfunction in Alzheimer’s Disease. Cell Metab. 2019;30:493–507 e496. doi: 10.1016/j.cmet.2019.06.005. - DOI - PubMed